Evidence map›Paper›PMID 1729269›Full record

ArticleThe Journal of clinical investigation1992

Increased lipolysis and its consequences on gluconeogenesis in non-insulin-dependent diabetes mellitus.

N Nurjhan, A Consoli, J Gerich

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 197 citations in OpenAlex.

  1. Trial
  2. Insulin receptorNature communications · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Metabolic Action of Metformin.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  13. Article
  14. Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Ameliorative property ofSaudi journal of biological sciences · 2021
    Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

N NurjhanDepartment of Medicine, University of Pittsburgh School of Medicine, Pennsylvania 15261.
A Consoli
J Gerich
University of Pittsburgh · US

Funding

WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MANR01DK020411 · NIDDK · UNIVERSITY OF ROCHESTER · PI GERICH, JOHN E · 1996 to 2007
$2.7M
ALPHA AND BETA CELL FUNCTION IN HUMAN DIABETESR37DK020411 · NIDDK · WHITTIER INSTITUTE FOR DIABETES &ENDOC · PI GERICH, JOHN E · 1986 to 1993
–
NCRR NIH HHS M501 RR-00056NIDDK NIH HHS DK-20411
6 · The paper itself

Abstract

The present studies were undertaken to determine whether lipolysis was increased in non-insulin-dependent diabetes mellitus (NIDDM) and, if so, to assess the influence of increased glycerol availability on its conversion to glucose and its contribution to the increased gluconeogenesis found in this condition. For this purpose, we infused nine subjects with NIDDM and 16 age-, weight-matched nondiabetic volunteers with [2-3H] glucose and [U-14C] glycerol and measured their rates of glucose and glycerol appearance in plasma and their rates of glycerol incorporation into plasma glucose. The rate of glycerol appearance, an index of lipolysis, was increased 1.5-fold in NIDDM subjects (2.85 +/- 0.16 vs. 1.62 +/- 0.08 mumol/kg per min, P less than 0.001). Glycerol incorporation into plasma glucose was increased threefold in NIDDM subjects (1.13 +/- 1.10 vs. 0.36 +/- 0.02 mumol/kg per min, P less than 0.01) and accounted for twice as much of hepatic glucose output (6.0 +/- 0.5 vs. 3.0 +/- 0.2%, P less than 0.001). Moreover, the percent of glycerol turnover used for gluconeogenesis (77 +/- 6 vs. 44 +/- 2, P less than 0.001) was increased in NIDDM subjects and, for a given plasma glycerol concentration, glycerol gluconeogenesis was increased more than two-fold. The only experimental variable significantly correlated with the increased glycerol gluconeogenesis after taking glycerol availability into consideration was the plasma free fatty acid concentration (r = 0.80, P less than 0.01). We, therefore, conclude that lipolysis is increased in NIDDM and, although more glycerol is thus available, increased activity of the intrahepatic pathway for conversion of glycerol into glucose, due at least in part to increased plasma free fatty acids, is the predominant mechanism responsible for enhanced glycerol gluconeogenesis. Finally, although gluconeogenesis from glycerol in NIDDM is comparable to that of alanine and about one-fourth that of lactate is terms of overall flux into glucose, glycerol is probably the most important gluconeogenic precursor in NIDDM in terms of adding new carbons to the glucose pool.

Indexed as

Blood GlucoseCase-Control StudiesDiabetes Mellitus, Type 2Fatty Acids, NonesterifiedFemaleGlucagonGluconeogenesisGlycerolHumansInfusions, IntravenousInsulinLipolysisMaleRadioactive TracersBlood GlucoseFatty Acids, NonesterifiedGlucagonGlycerolInsulinRadioactive Tracers

Identifiers

PMID1729269
PMCPMC442833
OpenAlexW2017914427

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.